Markers of progression in IgA nephropathy
Schena, F.P.; Gesualdo, L.
Journal of Nephrology 14(6): 554-574
2001
ISSN/ISBN: 1121-8428 PMID: 11783611 Document Number: 531799
Document emailed within 1 workday
Related Documents
Nyberg, G.; Nordén, G.; Björck, S.; Larsson, O. 1988: Progression of diabetic nephropathy--a multifactorial process Scandinavian Journal of Urology and Nephrology. Supplementum 108: 35-40Hovind, P. 2005: Initiation, progression and remission of diabetic nephropathy Danish Medical Bulletin 52(4): 119-142
Maixnerová, D.; Merta, M.; Reiterová, J.; Stekrová, J.; Rysavá, R.; Obeidová, H.; Viklický, O.; Potmĕsil, P.; Tesar, V. 2007: The influence of three endothelin-1 polymorphisms on the progression of IgA nephropathy Folia Biologica 53(1): 27-32
Magistroni, R.; Furci, L.; Leonelli, M.; Masellis, M.; Ligabue, G.; Lucchi, L.; Lupo, A.; Brezzi, B.; Gambaro, G.; Manganelli, L.; Pedrazzi, G.; Ricardi, M.; Bormioli, L.; Albertazzi, A. 2006: A validated model of disease progression in IgA nephropathy Journal of Nephrology 19(1): 32-40
Senatorski, G.; Paczek, L.; Kropiewnicka, E.; Bartłomiejczyk, I. 2002: Cytokines in noninvasive diagnostics of diabetic nephropathy progression Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 13(Suppl 1): 28-32
González, E.; Ortiz, M.; Praga, M. 2001: Diabetes and kidneys: predictors of nephropathy and progression factors Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 21(Suppl 3): 46-51
Nicholls, K. 2007: Prevention of progression of kidney disease: diabetic nephropathy - CARI guidelines Australian Family Physician 36(3): 137-138
Loveday, C. 1995: Virological markers of progression: a UK experience Journal of Biological Regulators and Homeostatic Agents 9(3): 100-104
Gupta, V.; Gupta, S. 2004: Laboratory markers associated with progression of HIV infection Indian Journal of Medical Microbiology 22(1): 7-15
Remuzzi, G. 2000: Renal protection: progression, regression, remission from nephropathy beyond blood pressure control International Journal of Clinical Practice. Supplement 2000(110): 9-15
Serov, V.V.; Iushkov, P.V.; Ivanov, P.K. 1993: Possible markers of the progression and ulcerogenesis of stomach cancer Arkhiv Patologii 55(2): 9-12
Magyarlaki, T.; Davin, J.C.; Szabados, E.; Kocsis, B.; Nagy, J. 1990: Peripheral B-lymphocyte markers and function in IgA nephropathy Clinical Nephrology 33(3): 123-129
Pierce, H.L.; Stevermer, J.J. 2001: Does losartan (Cozaar) slow the progression of renal disease in patients with type 2 diabetes and nephropathy? Journal of Family Practice 50(12): 1083
Mukai, Y.; Murata, M. 2017: Japan Parkinson's Progression Markers Initiative (J-PPMI) Nihon Rinsho. Japanese Journal of Clinical Medicine 75(1): 151-155
Conri, C.; Simonoff, M.; Constans, J.; Fleury, H. 1992: Are zinc and selenium markers of progression in HIV infected patients? Presse Medicale 21(30): 1435
Krairittichai, U.; Sarinnapakorn, V.; Mahannopkul, R.; Ainwan, P. 2017: Renal Protective Effects of Combination of Diltiazem and ACEI/ARB on the Progression of Diabetic Nephropathy: Randomized Controlled Trial Journal of the Medical Association of Thailand 100(Suppl 1): S40-S47
Topchii, I.; Semenovykh, P.; Galchiskaya, V.; Yakymenko, Y.; Shcherban, T. 2019: Association of Fibroblast Growth Factor 23 with Markers of Inflammation and Fibrosis in Diabetic Nephropathy Georgian Medical News 2019(292-293): 44-49
Grandjouan, S.; Henry, I.; Haliassos, A. 1991: Molecular analysis of genes involved in colorectal tumors. Markers of tumor predisposition and progression Gastroenterologie Clinique et Biologique 15(1): 34-48
Ranieri, E.; Gesualdo, L.; Grandaliano, G.; Maiorano, E.; Schena, F.P. 2001: The role of alpha-smooth muscle actin and platelet-derived growth factor-beta receptor in the progression of renal damage in human IgA nephropathy Journal of Nephrology 14(4): 253-262
Schechter, M.; Harrison, L.H.; Halsey, N.A.; Trade, G.; Santino, M.; Moulton, L.H.; Quinn, T.C. 1994: Coinfection with human T-cell lymphotropic virus type I and HIV in Brazil. Impact on markers of HIV disease progression JAMA 271(5): 353-357